Evidence map›Paper›PMID 41160025›Full record

ArticleJAMA network open2025

Schizophrenia, Bipolar, or Major Depressive Disorder and Postacute Sequelae of COVID-19.

Veer Vekaria, Rohith Kumar Thiruvalluru, Zoe Verzani, Sajjad Abedian, Mark Olfson, Braja Gopal Patra, Yunyu Xiao, Katherine S Salamon, Karin Hoth, Frank Blancero and 8 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Veer VekariaWeill Cornell Medicine, New York, New York.
Rohith Kumar ThiruvalluruWeill Cornell Medicine, New York, New York.
Zoe VerzaniWeill Cornell Medicine, New York, New York.
Sajjad AbedianWeill Cornell Medicine, New York, New York.
Mark OlfsonNew York State Psychiatric Institute, Columbia University, New York.
Braja Gopal PatraWeill Cornell Medicine, New York, New York.
Yunyu XiaoWeill Cornell Medicine, New York, New York.
Katherine S SalamonNemours Children's Health, Wilmington, Delaware.
Karin HothDepartment of Psychiatry, University of Iowa, Iowa City.
Frank BlanceroRECOVER Patient, Caregiver, or Community Advocate Representative, New York, New York.
Maxwell M Hornig-RohanRECOVER Patient, Caregiver, or Community Advocate Representative, New York, New York.
Teresa AkintonwaRECOVER Patient, Caregiver, or Community Advocate Representative, New York, New York.
Mahfuza SabihaWeill Cornell Medicine, New York, New York.
Mark G WeinerWeill Cornell Medicine, New York, New York.
Thomas W CartonLouisiana Public Health Institute, New Orleans, Louisiana.
Rainu KaushalWeill Cornell Medicine, New York, New York.
Jyotishman PathakWeill Cornell Medicine, New York, New York.
RECOVER PCORnet EHR consortium

Funding

Linking VA and non-VA data to study the risk of suicide in chronic pain patients.R01MH121907 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI OSLIN, DAVID W., PATHAK, JYOTISHMAN · 2020 to 2024
$3.6M
4/4: Leveraging EHR-linked biobanks for deep phenotyping, polygenic risk score modeling, and outcomes analysis in psychiatric disordersR01MH121922 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI PATHAK, JYOTISHMAN · 2019 to 2023
$2.0M
NIMH NIH HHS R01 MH121907NIMH NIH HHS R01 MH121922
6 · The paper itself

Abstract

Importance: Given the increased vulnerability to COVID-19 among those with a serious mental illness (SMI), it remains unclear whether these individuals face a higher risk of developing postacute sequelae of SARS-CoV-2 (PASC). Understanding this association could inform secondary prevention efforts. Objective: To identify the risk of developing PASC in patients with an SMI. Design, Setting, and Participants: This longitudinal cohort study used data derived from large-scale electronic health records (EHRs) between March 2020 and April 2023, inclusive of 180-day follow-up. Patients included adults aged 21 years or older with a confirmed COVID-19 infection evidenced by a relevant laboratory result, diagnosis, or prescription order. Exposures: Evidence of an SMI diagnosis (schizophrenia, bipolar disorder, or recurrent major depressive disorder) recorded before COVID-19 infection. Main Outcomes and Measures: Evidence of PASC symptoms within 30 to 180 days' follow-up after COVID-19 infection reported as odds ratios (OR) mutually adjusted for age, sex, race and ethnicity, insurance type, Charlson Comorbidity Index (CCI) score, and COVID-19 severity. Results: A total of 1 625 857 patients with a COVID-19 infection were included (mean [SD] age, 52 [17] years; 998 237 [61.4%] female, 204 237 [12.6%] non-Hispanic Black, 219 220 [13.5%] Hispanic, 833 411 [51.3%] non-Hispanic White, and 1 228 664 [75.6%] urban patients), of whom 258 523 (15.9%) had an SMI and 403 641 (24.8%) developed PASC. Individuals with an SMI had increased adjusted odds of developing PASC (OR, 1.10; 95% CI, 1.08-1.11; P < .001). Variables associated with greater odds of PASC among the study population included older age compared with age 22 to 34 years (35 to 44 years: OR, 1.04; 95% CI, 1.03-1.06; 45 to 64 years: OR, 1.11; 95% CI, 1.10-1.12; ≥65 years: OR, 1.18; 95% CI, 1.17-1.20), non-Hispanic Black and Hispanic compared with non-Hispanic White race and ethnicity (non-Hispanic Black: OR, 1.08; 95% CI, 1.07-1.10; Hispanic: OR, 1.12; 95% CI, 1.11-1.13), higher chronic disease burden vs no chronic disease (CCI 1 to 3: OR, 1.13; 95% CI, 1.12-1.14; CCI ≥4: OR, 1.23; 95% CI, 1.22-1.25), and hospitalization with initial COVID-19 infection vs no hospitalization (hospitalized: OR, 1.80; 95% CI, 1.77-1.82; hospitalized with ventilation: OR, 2.17; 95% CI, 2.12-2.22; P < .001). Compared with public insurance, commercial health insurance was associated with lower odds of PASC (OR, 0.85; 95% CI, 0.84-0.86). Conclusions and Relevance: In this cohort study of patients infected with COVID-19, patients with SMI compared with those without SMI were at increased risk of PASC, underscoring the need for coordinated mental health and COVID-19 care strategies.

Indexed as

Bipolar DisorderCOVID-19Major Depressive DisorderSchizophreniaAdultAgedComorbidityFemaleHumansLongitudinal StudiesMaleMiddle AgedPost-Acute COVID-19 SyndromeRisk FactorsSARS-CoV-2

Identifiers

PMID41160025
PMCPMC12573031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.